JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Trump Says Anthropic No Longer Seen as National Security Threat 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
LEXINGTON, Mass., Feb. 01, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the BIO CEO & Investor Conference, February 8, 2016, at 5:30 p.m. Eastern Time in New York City.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.veracast.com/webcasts/bio/ceoinvestor2016/89132240349.cfm
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
